{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.4","upperLimit":"62.2","value":"52.4"},{"groupId":"OG001","lowerLimit":"50.6","upperLimit":"77.3","value":"64.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"description":"DCR is defined as the percentage of participants who have a CR or PR or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease). The DCR per RECIST 1.1 as assessed by BICR is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months).","id":"OG000","title":"Recurrent or Metastatic Cutaneous cSCC Cohort"},{"description":"Participants received pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months).","id":"OG001","title":"Locally Advanced Unresectable cSCC Cohort"}],"paramType":"NUMBER","populationDescription":"The analysis population consisted of all participants who received ≥1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 56 months","title":"Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}